Pembrolizumab Monotherapy for Relapsed/Refractory Classical Hodgkin Lymphoma: 5-Year Follow-Up of KEYNOTE-087
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Blood
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Five-year follow-up of KEYNOTE-087: pembrolizumab monotherapy in relapsed/refractory classical Hodgkin lymphoma
Blood 2023 Jun 15;[EPub Ahead of Print], P Armand, PL Zinzani, HJ Lee, NA Johnson, P Brice, J Radford, V Ribrag, D Molin, TP Vassilakopoulos, A Tomita, B von Tresckow, MA Shipp, AF Herrera, J Lin, E Kim, S Chakraborty, P Marinello, CH MoskowitzFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.